This has been a great year for the overall stock market and a banner year for a handful of drugmakers that don't even have a product to sell yet.
These three biotech stocks entered 2019 ready to provide market-thumping returns, and they delivered. Let's look at what made them the industry's top stocks this year to see if they can do it again in 2020 and beyond.
Data source: Yahoo! Finance.
Unnecessary blood vessel growth in the retina is the leading cause of progressive blindness in older adults, and injections of vascular endothelial growth factor (VEGF) inhibitors to halt that growth is a huge business. Sales of the leading VEGF inhibitor, Eylea from Regeneron (NASDAQ:REGN) reached a whopping $5.5 billion during the first nine months of 2019 but could face fierce competition soon from Kodiak Sciences' lead candidate, KSI-301, in a few short years.
With Eylea, patients need to receive injections every other month, and there's usually a few days between doses where patients aren't protected. Shares of Kodiak Sciences soared this year thanks to surprisingly good results from a VEGF inhibitor called KSI-301, which show it remains at therapeutic concentrations for more than twice as long as Eylea.
Kodiak recently secured $225 million in financing from one of the most successful biotech-focused funds on the planet, Baker Brothers, in return for a 4.5% royalty on KSI-301's potential sales. The company will use the funds to run pivotal studies that could lead to Food and Drug Administration (FDA) approval in 2022 of KSI-301 for the treatment of retinal vein occlusion. Also in 2022, the company expects to submit applications that could expand KSI-301's purview to age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Image source: Getty Images.
Patients with myelofibrosis produce so many unnecessary blood cells that their bone marrow becomes permanently damaged. Blood cell overproduction also causes the spleen to swell, along with a variety of other symptoms.
There's just one myelofibrosis treatment at the moment, Jakafi from Incyte (NASDAQ:INCY). Jakafi's a kinase inhibitor that reduces blood cell proliferation for the vast majority of myelofibrosis patients, but its benefits tend to drop off after a few years. Constellation Pharmaceuticals stock soared this year after an interim analysis of an ongoing study with its lead candidate, CPI-0601, which produced some compelling evidence of efficacy for patients who had stopped responding to Jakafi.
Constellation's lead candidate is a potential first-in-class BET inhibitor thatreduced spleen volume for 94% of patients and reduced total symptom scores for 93% of patients. Among a subset of 13 patients who relied on frequent blood transfusions going into the study, four became transfusion independent.
Constellation will begin a placebo-controlled pivotal trial in 2020 with CPI-0601 plus Jakafi. Sales of Incyte's drug are expected to reach $1.7 billion in 2019, and CPI-0601 sales could peak at more than $1 billion annually if it continues to produce results in line with those we've already seen.
Image source: Getty Images.
Neurology's come a long way in recent years, but the brain is so complex that we still don't understand the root cause of most mental health issues. One thing we're sure of is that certain drugs tend to amplify each other's effects when combined.
Instead of relying on trial and error to come up with a new depression drug, Axsome Therapeutics is taking advantage of a well-known interaction between bupropion, a decades-old antidepressant, and dextromethorphan, the main ingredient in over-the-counter cough syrup.
There wasn't a lot of enthusiasm for AXS-05 at the beginning of 2019, but one clinical trial victory after another has sent the stock higher. Around 16 million Americans experience a bout of major depressive disorder each year, but available treatments don't get the job done for a majority of them. If AXS-05 earns a widely expected approval to treat this enormous population, the stock could keep on rising in 2020 and beyond.
Now that the market caps of these three drugmakers have reached 10 figures, another year like 2019 isn't likely. For example, if Axsome were to repeat its 2019 performance, it would end 2020 worth about as much asAmgen.
Another year of market-beating gains, though, is well within the realm of possibility for all three of these biotech stocks. Although nobody's ever gone broke by taking profits following huge run-ups, it's probably a good idea to hang on to shares of these stocks for the long run.
Read this article:
3 Biotech Stocks That Crushed It in 2019 - The Motley Fool
- AI has perfect detection rate for severe cases of condition that causes blindness in preemies - OHSU News - March 10th, 2024
- PulseSight launches with gene therapy platform targeting age-related blindness - Longevity.Technology - March 10th, 2024
- AIOS and RANZCO Unite to Combat Preventable Blindness - Hindustan Times - March 10th, 2024
- Baby born without eyes defies the odds as she thrives despite blindness - Express - March 10th, 2024
- Penn Medicine Accelerator Program to Boost AI-Powered Projects Targeting Blindness and Cervical Cancer - India Education Diary - March 10th, 2024
- Scientists discover gut bacteria`s role in genetically-linked vision loss - WION - February 27th, 2024
- Prevent Blindness launches new Retinopathy of Prematurity Education and Support Program as part of inaugural ... - Modern Retina - February 27th, 2024
- Revolutionizing Eye Disease Treatment: The Unseen Link Between Gut Bacteria and Blindness - Medriva - February 27th, 2024
- The Virtue of Color-Blindness & The End of Race Politics: Arguments for a Colorblind America Book Review - National Review - February 27th, 2024
- Sight loss could be treated by antibiotics after being linked to gut bacteria - The Independent - February 27th, 2024
- Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of ... - PR Web - February 27th, 2024
- $35 million to fight blindness with manufactured corneas | Health Portfolio Ministers | Australian Government ... - Department of Health - February 10th, 2024
- Eye care, vision impairment and blindness - World Health Organization (WHO) - October 27th, 2023
- CHOROIDEREMIA RESEARCH FOUNDATION EXPANDS RESEARCH SUPPORT INTO NONSENSE MUTATIONS OF A RARE INHERITED RETINAL - EIN News - May 1st, 2023
- Chennai eye hospital ties up with Iceland firm to adopt mathematical algorithm to predict diabetic retinopathy - The Hindu - April 23rd, 2023
- Drug-Resistant Bacteria Tied to Eyedrops Can Spread Person to Person ... - April 7th, 2023
- Prevention of Blindness Week 2023: Mumbai experts explain why you should be concerned about glaucoma and the need for regular eye checkups -... - April 7th, 2023
- Childhood blindness - Wikipedia - February 24th, 2023
- FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of ... - February 24th, 2023
- Human mini brains illuminate path to curing blindness - February 16th, 2023
- Raymond V. Gilmartin: Man with a global vision - February 16th, 2023
- Why Are People So Mad About MrBeast's Blindness Video? - February 16th, 2023
- This heartwarming video of a colorblind boy seeing color for the first time will make you cry - Indiatimes.com - February 16th, 2023
- Blindness (Vision Impairment): Types, Causes and Treatment - February 8th, 2023
- CDC urges people to stop using brand of artificial tears linked to ... - February 8th, 2023
- Health News Roundup: U.S. FDA says India-made eye drop linked to some infections, blindness and one death; China records 3,278 COVID-related deaths... - February 8th, 2023
- I had two strokes at 29 and gone blind -I've been accused of faking my sight loss - Daily Mail - February 8th, 2023
- Blindness and vision impairment - World Health Organization - January 23rd, 2023
- Recovery from blindness - Wikipedia - January 23rd, 2023
- Colour blindness tests, juggling, avoiding glare: A hockey goalkeepeers quest to train his biggest weapon, eyes - The Indian Express - January 23rd, 2023
- But Did You See the Gorilla? The Problem With Inattentional Blindness ... - October 15th, 2022
- Canadians unaware of diseases that lead to blindness, survey says - CTV News Northern Ontario - October 15th, 2022
- A Review of Corneal Blindness: Causes and Management - Cureus - October 15th, 2022
- A cure for blindness may be first product made in space - Freethink - October 15th, 2022
- Is MrBeast trying to cure 1000 people's blindness? - indy100 - October 15th, 2022
- Early detection and management is the key to prevent glaucoma related blindness: Experts - Express Healthcare - October 15th, 2022
- As World Sight Day Nears, River Blindness is Fading - SaportaReport - October 15th, 2022
- Tears of happiness: How curing blindness in Dolakha saved a girls future - City A.M. - October 15th, 2022
- World Sight Day: Orbis, UC Davis team up to train eye care teams from Latin America to fight avoidable blindness - Ophthalmology Times - October 15th, 2022
- Juan Williams: The GOPs epidemic of intentional blindness - The Hill - October 15th, 2022
- Charles pays tribute to Malawi's elimination of disease causing blindness - Express & Star - October 15th, 2022
- Coping with calamity: Former NYT columnist Frank Bruni on blindness and vision, at Morristown book fest keynote - Morristown Green - October 15th, 2022
- Sighting solutions in a world of vision for weavers - The New Indian Express - October 15th, 2022
- Blindfold run raises $40,000 for the MUHC Foundation to support glaucoma care at the MUHC - StreetInsider.com - October 15th, 2022
- MacKenzie Scott Donates $15M to Address the Eyecare Needs of the Impoverished - InvisionMag - October 15th, 2022
- Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -... - September 20th, 2022
- Treating cataracts before 'critical age' imperative FBC News - FBC News - September 20th, 2022
- GenSight Biologics to Present at Upcoming Industry and Investor Conferences - Business Wire - September 20th, 2022
- Ashton Kutcher battled vasculitis causing blindness, loss of hearing. Know all about the rare condition - India TV News - August 11th, 2022
- Prevent Blindness Is Recognized as a Healthy People 2030 Champion for Supporting the Initiative's Vision - Vision Monday - August 11th, 2022
- Researchers make progress toward a stem cellbased therapy for blindness - Ophthalmology Times - August 11th, 2022
- The strategic blindness of Israel's caretaker government - JNS.org - August 11th, 2022
- UND professor carries the torch for UND studies of visual impairment and blindness - Grand Forks Herald - August 11th, 2022
- Karan Nagrani is using social media to raise awareness about the 'spectrum of blindness' - ABC News - August 11th, 2022
- Vision impairment and blindness related to NCDs: Fong - FBC News - August 11th, 2022
- Strategic blindness of caretaker government - The Jewish Star - August 11th, 2022
- Massachusetts woman blinded by attack working to help others regain sight - WCVB Boston - August 11th, 2022
- Persuasion Film Review: Is Heterogeneous Casting Race-Inclusionary Or Escapist? - Feminism In India - August 11th, 2022
- Is It Time To Start Using Race And Gender To Combat Bias In Lending? - Forbes - August 11th, 2022
- The journey of Kali Yugi started with the mistake of objectives! - Youthistaan - August 11th, 2022
- A 50-State Review of Access to State Medicaid Program Information for People with Limited English Proficiency and/or Disabilities Ahead of the PHE... - August 11th, 2022
- iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for... - August 11th, 2022
- Vitamin B12: Why You Need It & Foods To Increase Your Vitamin B12 Intake - NDTV - August 11th, 2022
- Jack Levine: Remembering a dad who proved that even in blindness, there can be vision - The Florida Times-Union - June 26th, 2022
- Potion of Blindness | Minecraft Ideas Wiki | Fandom - June 26th, 2022
- Tightening a molecular "zipper" could help prevent hereditary blindness - New Atlas - June 26th, 2022
- What's the Link Between Glaucoma and Dry Eyes? - Healthline - June 26th, 2022
- Lisa Durden's upcoming documentary "Blind Divas" follows Krystle Allen and Naquela Wright-Prevoe, two Black women entrepreneurs, determined... - June 26th, 2022
- Trump election lies may fit legal concept of willful blindness - Chicago Tribune - June 26th, 2022
- Sightsavers relaunches its thematic strategy The Sun Nigeria - Daily Sun - June 26th, 2022
- Trachoma elimination: millions more to benefit from donated azithromycin - World Health Organization - June 26th, 2022
- Dangers of super gonorrhoea from infertility to blindness as global warning issued - Daily Star - June 26th, 2022
- Fifty years of Title IX: What is it, what does it cover and do we still need it? - The Athletic - June 26th, 2022
- How The SMH Got That Rebel Wilson Story So Wrong - Junkee - June 26th, 2022
- The Week That Was: All of Lawfare in One Post - Lawfare - Lawfare - June 26th, 2022
- Why Brad Pitt quit smoking and drinking altogether during the pandemic - BusinessGhana - June 26th, 2022
- Watch your eye - The New Indian Express - June 26th, 2022
- Olivia Brouwer's art is for everyone to see and touch - Hamilton Spectator - June 26th, 2022
- Monkeypox may not mutate as fast as coronaviruses, but that doesn't mean it can't adapt to its new hosts - The Conversation - June 26th, 2022
- Former American Express Foundation President Takes Helm of Signature Theatre - The Chronicle of Philanthropy - June 26th, 2022